Teva Stock Dives 14%. 'We're Victims Of Our Own Success,' Says CEO.

Published on 29 Jan 2025 on Investor's Business Daily

Still, in midday trades, Teva stock tumbled 14% to 18.52. Shares undercut their 50-day moving...

Read the rest of the article

Start tracking your investments with Statfolio

European stock markets rose Thursday, as investors digested a deluge of corporate earnings ahead ...

Investing.com 30 Jan 2025

Sanofi (EPA:SASY) (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.2...

Investing.com 30 Jan 2025

(Bloomberg) -- Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits...

Bloomberg · via Yahoo Finance 30 Jan 2025

-Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year an...

Reuters · via Yahoo Finance 30 Jan 2025

Still, in midday trades, Teva stock tumbled 14% to 18.52. Shares undercut their 50-day moving...

Investor's Business Daily 29 Jan 2025

We recently compiled a list of the 10 Best European Bank Stocks to Buy According to Analysts. In...

Insider Monkey · via Yahoo Finance 27 Jan 2025

Novo Nordisk declined the most (36.6%). (See the last pharma stock roundup here: Pharma Stock...

Zacks · via Yahoo Finance 24 Jan 2025

Sanofi (SNY) has received EU regulatory approval for its drug Sarclisa for the treatment of newly...

Seeking Alpha 22 Jan 2025

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article...

Insider Monkey · via Yahoo Finance 22 Jan 2025

The U.S. Food and Drug Administration (FDA) issued a warning letter to Sanofi SA’s SNY Genzyme Co...

Benzinga 22 Jan 2025